Simplify Asset Management Inc. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Simplify Asset Management Inc. lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,258 shares of the biopharmaceutical company’s stock after selling 3,333 shares during the quarter. Regeneron Pharmaceuticals makes up 0.2% of Simplify Asset Management Inc.’s holdings, making the stock its 27th biggest position. Simplify Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $4,458,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Intact Investment Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $356,000. Golden State Equity Partners increased its position in shares of Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 1,272 shares in the last quarter. Fagan Associates Inc. raised its stake in shares of Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after buying an additional 3,832 shares during the period. Finally, ABC Arbitrage SA purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $1,510,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent analyst reports. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $658.48 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The stock’s fifty day moving average is $689.43 and its two-hundred day moving average is $815.71. The company has a market capitalization of $71.99 billion, a P/E ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $11.86 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.